Search research articles
Contact Us
Filters
Showing results (441-450 of 470) with videos related to
Page
of 47
Sort By:
Cancer Cell
|
September 29, 2023
Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden
Mingrui Zhu, Jiwoong Kim, Qing Deng, et al.
Clinical and Experimental Medicine
|
September 4, 2024
Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma
Ruixue Ma, Qi Zhang, Yang Liu, et al.
International Urology and Nephrology
|
May 1, 2025
Nephrotoxicity of CAR-T therapy in patients with relapsed and refractory multiple myeloma
Zihan Chen, Yegan Chen, Jiaying Liu, et al.
Nature Communications
|
April 20, 2024
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial
Ming Shi, Jiaojiao Wang, Hongming Huang, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 11, 2025
Summer and nonsummer climatic signals in speleothem δ<sup>18</sup>O revealed by loess microcodium δ<sup>18</sup>O in East Asia
Zeke Zhang, Zhengyu Liu, Gaojun Li, et al.
American Journal of Hematology
|
February 18, 2022
Safety and efficacy of a humanized CD19 chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic leukemia
Ming Shi, Li Li, Shiyuan Wang, et al.
Clinical and Experimental Medicine
|
November 1, 2023
Long-term analysis of cellular immunity in patients with RRMM treated with CAR-T cell therapy
Hai Cheng, Shengwei Ji, Jiaojiao Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 14, 2019
Rainfall variations in central Indo-Pacific over the past 2,700 y
Liangcheng Tan, Chuan-Chou Shen, Ludvig Löwemark, et al.
American Journal of Hematology
|
August 28, 2024
Clinical outcomes and microenvironment profiling in relapsed/refractory multiple myeloma patients with extramedullary disease receiving anti-BCMA CAR T-cell-based therapy
Yuekun Qi, Hujun Li, Kunming Qi, et al.
The Lancet. Haematology
|
July 26, 2024
Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial
Dian Zhou, Qian Sun, Jieyun Xia, et al.
Page
of 47
Search research articles
Search
Showing results (441-450 of 470) with videos related to
Sort By:
Page
of 47
Cancer Cell
|
September 29, 2023
Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden
Mingrui Zhu, Jiwoong Kim, Qing Deng, et al.
Clinical and Experimental Medicine
|
September 4, 2024
Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma
Ruixue Ma, Qi Zhang, Yang Liu, et al.
International Urology and Nephrology
|
May 1, 2025
Nephrotoxicity of CAR-T therapy in patients with relapsed and refractory multiple myeloma
Zihan Chen, Yegan Chen, Jiaying Liu, et al.
Nature Communications
|
April 20, 2024
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial
Ming Shi, Jiaojiao Wang, Hongming Huang, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 11, 2025
Summer and nonsummer climatic signals in speleothem δ<sup>18</sup>O revealed by loess microcodium δ<sup>18</sup>O in East Asia
Zeke Zhang, Zhengyu Liu, Gaojun Li, et al.
American Journal of Hematology
|
February 18, 2022
Safety and efficacy of a humanized CD19 chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic leukemia
Ming Shi, Li Li, Shiyuan Wang, et al.
Clinical and Experimental Medicine
|
November 1, 2023
Long-term analysis of cellular immunity in patients with RRMM treated with CAR-T cell therapy
Hai Cheng, Shengwei Ji, Jiaojiao Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 14, 2019
Rainfall variations in central Indo-Pacific over the past 2,700 y
Liangcheng Tan, Chuan-Chou Shen, Ludvig Löwemark, et al.
American Journal of Hematology
|
August 28, 2024
Clinical outcomes and microenvironment profiling in relapsed/refractory multiple myeloma patients with extramedullary disease receiving anti-BCMA CAR T-cell-based therapy
Yuekun Qi, Hujun Li, Kunming Qi, et al.
The Lancet. Haematology
|
July 26, 2024
Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial
Dian Zhou, Qian Sun, Jieyun Xia, et al.
Page
of 47